The promise of breakthrough prescription drugs has created an sudden disaster in employer advantages. As GLP-1 medicines reveal exceptional efficacy for weight administration and persistent illness prevention, their prices have turn into untenable for many companies. The numbers inform the story: U.S. prescription drug spending hit $805.9B in 2024, climbing 10.2% year-over-year, whereas two-thirds of employers have dropped GLP-1 protection totally relatively than face projected healthcare price will increase of 10% in 2026. Andel is constructing a membership platform that sidesteps the standard pharmacy profit supervisor infrastructure, aggregating worker demand throughout a number of employers to barter immediately with producers. The cooperative mannequin permits employers to contribute subsidies at no matter stage suits their finances whereas members pay a small month-to-month charge for entry, making a profit construction that doesn’t require employers to soak up the total price of protection.
AlleyWatch sat down with Andel CEO and Cofounder Jay Bregman to be taught extra concerning the enterprise, the longer term plans, current fudning spherical, and far, a lot, extra…
Who have been your traders and the way a lot did you increase?
Andel’s traders embrace Lightbank, Seedcamp, Bertelsmann Healthcare Investments, Houghton Avenue Ventures, and Springboard Well being Angels, backing a seed spherical of $4.5M.
Inform us concerning the services or products that Andel gives.
Andel is a revolution in drug affordability — a cooperative worker platform that unlocks entry to GLP-1s and different brand-name medicines. Workers want these medicines, however employers can’t afford to cowl them.
We remedy this drawback by leveraging the mixed shopping for energy of our members to go immediately to producers for higher costs and a assured provide. Then, employers add a subsidy of their selecting to additional scale back prices to members.
What impressed the beginning of Andel?
My household comes from drugs and I had at all times needed to construct a healthcare startup. As my fourth enterprise, I felt I may take a giant swing and remedy crucial drawback in American healthcare: model title prescription pricing and distribution.
I noticed the ability of GLP-1s and different next-generation brand-name medication and I puzzled why it was so troublesome for individuals to entry them. It appeared like having access to generic older medication was simple however actually life-changing medicines have been out of attain. It felt like a ‘miracle drug paradox’ the place pharma was inventing actually wonderful therapies however the higher they have been and extra individuals that would profit the less and fewer individuals have been truly getting them. It felt just like the market was crying out for a brand new mannequin.
Ritu (cofounder) and I’ve the experience wanted to unravel this drawback. I’ve raised greater than $250 million and efficiently exited three firms, together with the ridesharing community Hailo, which went on to turn into Lyft Europe, and Thimble, which was later acquired by Arch Insurance coverage.
Ritu is a former senior govt at CVS Caremark and a licensed pharmacist with over 20 years main the business’s largest profit consulting corporations at Segal and Pharmaceutical Methods Group.
How is Andel completely different?
Andel’s platform combines producer’s reductions with employer subsidies to cut back prices for members. We ship the capabilities of a licensed pharmacy by means of a user-friendly digital platform that gives an unbelievable member expertise.
Finally, our aim is to turn into what I wish to name the Spotify of the drug business: a central platform that facilitates the sale of products even when it’s not making them itself.
Employers pay nothing for this system, in contrast to different options, and since we generate income by means of a small month-to-month charge charged to workers, our incentives are aligned with employers and workers to cut back drug prices and develop our membership as broadly as attainable.
What market does Andel goal and the way massive is it?
US prescription drug expenditures rose to $805.9B in 2024, a rise of 10.2% over the earlier 12 months. Globally it’s within the trillions of {dollars}.
Andel targets any plan sponsors who both have already dropped GLP-1 protection for weight reduction or are contemplating it. This might embrace employers of all sizes, unions, coalitions, and even well being plans. Andel may also carry different medicines past GLP-1s which aren’t broadly coated by insurance coverage.
Though Andel is at present centered on the US market, we consider the dynamic of excessive drug prices (particularly pushed by MFN insurance policies) will enable us to broaden elsewhere in North America, Europe, and past.
What’s your small business mannequin?
We’re B2B2C, not direct-to-consumer. We don’t cost employers a charge and their subsidies are handed totally by means of to cut back the drug prices of their workers at level of sale. Workers are charged a small month-to-month charge to entry the community and their employer subsidies.
How are you getting ready for a possible financial slowdown?
We’re hiring a gross sales group. As a result of throughout financial downturns, the very first thing firms do is overview their advantages, and the primary profit prone to be minimize is GLP-1 protection and their pharmacy profit. That can imply they are going to be searching for alternate options that enable them to offer GLP-1 advantages in a more cost effective method.
For drug producers, a downturn means they are going to be searching for methods to broaden their payer channels, and Andel is an ideal strategy to tackle protection gaps and improve gross sales.
What was the funding course of like?
Ferocious. GLP-1 / model title entry and affordability is crucial subject going through humanity. Andel is a chance to assist construct a large enterprise whereas additionally fixing an important societal drawback, and that mixture solely comes alongside so very not often.
What are the largest challenges that you simply confronted whereas elevating capital?
The drug pricing market could be very complicated and obscure. Even some very good individuals suppose that the answer is for producers to easily scale back costs throughout the board, however that fails to acknowledge a key tenant of insurance coverage – when you will have a product that applies to nearly everybody in your inhabitants, costs must be 90% under present ranges to make that viable, and that would go away pharma firms no incentive to create the following life-changing drugs.
What components about your small business led your traders to write down the test?
A few of them knew me properly and that I may execute. Others noticed the progress we had made funding it ourselves and have been satisfied we may make it occur. Past that, the market was working in our favor, the relentless deal with decrease costs, innovation, and extra direct options have been super-helpful.
A few of them knew me properly and that I may execute. Others noticed the progress we had made funding it ourselves and have been satisfied we may make it occur. Past that, the market was working in our favor, the relentless deal with decrease costs, innovation, and extra direct options have been super-helpful.
What are the milestones you intend to attain within the subsequent six months?
Over the following six months, we’re centered on getting ready for our nationwide launch in early 2026: rising our employer community, deepening relationships with plan sponsors and pharmaceutical producers, and making certain an ideal expertise for the primary members who be a part of Andel.
What recommendation are you able to provide firms in New York that do not need a contemporary injection of capital within the financial institution?
Endure.
The place do you see the corporate going now over the close to time period?
We’re witnessing the most important seismic shift in the way in which medication are priced and distributed in US historical past. There’ll proceed to be an explosion in pharma D2C and direct-to-business shall be a pure complement to that. This may result in many thrilling pharma partnerships each for GLP-1s and different model medication.
Corporations of all sizes will proceed to drop GLP-1 protection for weight reduction and that may create hundreds of alternatives for Andel. Many will begin reviewing their protection for different model medication or courses as properly.
Within the close to time period, we’re centered on scaling thoughtfully, so we will broaden entry by means of employer and pharmacy partnerships, refine the member expertise, and lay the groundwork for a profitable nationwide launch in 2026.
The way forward for pharmaceutical entry shall be People paying membership charges for low-cost model medication, with pricing backed by their employer. Andel shall be as necessary as direct-to-consumer and insurance coverage to pharma producers and new medication shall be created primarily based on the truth that they don’t have to depend upon legacy insurance coverage firms for payback.
What’s your favourite fall vacation spot in and across the metropolis?
Battery Park.
You’re seconds away from signing up for the most well liked record in NYC Tech!
Enroll right this moment
